OverviewSuggest Edit

Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. Patients who suffer from rare diseases, such as nontuberculous mycobacteria (NTM) lung disease and pulmonary arterial hypertension (PAH), face multiple hurdles in finding effective treatments. Insmed is addressing the critical, unmet needs of these orphan patient populations. The company’s lead product candidate is an inhaled antibiotic that is in late-stage clinical development for serious lung infections caused by NTM. There are currently no approved therapies in the United States or European Union for NTM lung disease. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed. “Patients are at the center of everything we do and each of us brings a personal passion for advancing innovative therapies that can transform the lives of patients with rare diseases around the world.” The company is also developing INS1009, a nebulized treprostinil prodrug for the treatment of PAH. Insmed’s innovative focus is on the convenient dosing regimen, enhanced drug delivery, and lower systemic drug exposure which exemplifies its priority to improve patient comfort and care.
TypePublic
HQBridgewater, US
Websiteinsmed.com
Employee Ratings3

Latest Updates

Employees (est.) (Sep 2017)161
Job Openings45
Revenue (FY, 2018)$9.8 M(-14%)
Share Price (Mar 2019)$28.2 (-3%)

Key People/Management at Insmed

Kevin P. Tully

Kevin P. Tully

Evp & CFO
Steinar Engelsen

Steinar Engelsen

Member of the Board of Directors
Show more

Insmed Office Locations

Insmed has offices in Bridgewater, Amsterdam, Dublin, Frankfurt am Main and in 3 other locations
Bridgewater, US (HQ)
10 Finderne Ave
Paris, FR
1 Rue Favart
Frankfurt am Main, DE
49 Mainzer Landstraße
Dublin, IE
28 N Wall Quay
Amsterdam, NL
201 Barbara Strozzilaan
Utrecht, NL
328 Graadt van Roggenweg
Show all (7)
Report incorrect company information

Insmed Financials and Metrics

Insmed Revenue

Insmed's revenue was reported to be $9.84 m in FY, 2018
USD

Revenue (FY, 2018)

9.8m

Net income (FY, 2018)

(324.3m)

EBIT (FY, 2018)

(307.3m)

Market capitalization (22-Mar-2019)

2.2b

Closing stock price (22-Mar-2019)

28.2

Cash (31-Dec-2018)

495.1m
Insmed's current market capitalization is $2.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

11.5m9.8m

Revenue growth, %

(100%)

General and administrative expense

22.2m43.2m50.7m79.2m168.2m

R&D expense

44.3m74.3m122.7m109.7m145.3m
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

4.7m7.9m8.2m9.5m9.7m11.0m12.5m12.3m13.7m13.7m16.6m17.4m32.7m37.2m44.4m

R&D expense

12.1m14.9m15.2m17.2m18.2m19.2m20.5m23.9m23.4m22.3m26.9m26.7m30.1m35.7m39.5m

Operating expense total

16.8m22.8m23.4m26.7m28.0m30.2m33.1m36.1m37.1m36.0m43.5m44.1m62.8m72.9m84.0m

EBIT

(16.8m)(22.8m)(23.4m)(26.7m)(28.0m)(30.2m)(33.1m)(36.1m)(37.1m)(36.0m)(43.5m)(44.1m)(62.8m)(72.9m)(84.0m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

113.9m159.2m282.9m162.6m381.2m495.1m

Accounts Receivable

39.3m5.5m

Inventories

2.3m5.5m5.2m5.8m7.0m

Current Assets

116.2m164.7m288.1m168.4m389.4m518.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(56.1m)(79.2m)(118.2m)(176.3m)(192.6m)(324.3m)

Depreciation and Amortization

680.0k1.1m2.0m2.4m2.9m4.8m

Inventories

(7.0m)

Accounts Payable

(1.1m)3.3m(1.8m)2.8m3.6m3.9m
Quarterly
USDY, 2018

Financial Leverage

2.9 x
Show all financial metrics
Report incorrect company information

Insmed News and Updates

Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

BRIDGEWATER, N.J., Feb. 22, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,...

Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter

Shares of Insmed Incorporated shot up 18% in after-hours trading Friday after the company announced it expected sales of its antibacterial Arikayce to be $9.8 million for the fourth quarter, with $9.2 million in U.S. sales and $600,000 in sales outside the U.S. The drug is used to treat patients wi…

Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation...

PANTHERx® Specialty Pharmacy Selected by Insmed to Distribute ARIKAYCE® (amikacin liposome inhalation suspension)

PITTSBURGH, Dec. 18, 2018 /PRNewswire/ -- PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Insmed Incorporated to distribute ARIKAYCE® (amikacin liposome inhalation suspension), the first and only therapy specifically indicated for ...

Maxor selected by Insmed to be limited distribution provider of ARIKAYCE®

AMARILLO, Texas, Dec. 4, 2018 /PRNewswire/ -- Maxor National Pharmacy Services, LLC, a specialty pharmacy leader in pulmonary rare disease management, announced today that its family of specialty pharmacies have been selected as limited distribution providers of ARIKAYCE® (amikacin...

Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update

—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch—
Show more
Report incorrect company information

Insmed Blogs

Dewey Steadman

Dewey Steadman Mark.Pellegrino@INSM Wed, 01/02/2019 - 14:59 Dewey Steadman Canaccord Genuity

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to two new employees.

Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)

Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension) Content Import Thu, 10/11/2018 - 08:34 Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting En…

Insmed to Present at Two October Conferences

Insmed to Present at Two October Conferences Content Import Mon, 10/01/2018 - 08:05 Insmed to Present at Two October Conferences Oct 01,2018 This release is a backfill from a News Wire General BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE…

Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Tr

Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Tr Matthew.Mcgort… Fri, 09/28/2018 - 18:01 …

Insmed Frequently Asked Questions

  • Who are Insmed key executives?

    Insmed's key executives are Kevin P. Tully and Steinar Engelsen.

  • How many employees does Insmed have?

    Insmed has 161 employees.

  • What is Insmed revenue?

    Latest Insmed annual revenue is $9.8 m.

  • What is Insmed revenue per employee?

    Latest Insmed revenue per employee is $61.1 k.

  • Who are Insmed competitors?

    Competitors of Insmed include Array BioPharma, Remedi SeniorCare and ABIOMED.

  • Where is Insmed headquarters?

    Insmed headquarters is located at 10 Finderne Ave, Bridgewater.

  • Where are Insmed offices?

    Insmed has offices in Bridgewater, Amsterdam, Dublin, Frankfurt am Main and in 3 other locations.

  • How many offices does Insmed have?

    Insmed has 7 offices.